Mr. Ron Nagar reports

TEMPRAMED'S INDEPENDENTLY VALIDATED PAYER ROI MODEL FOR REIMBURSEMENT FURTHER REINFORCED BY A SCIENTIFIC PUBLICATION HIGHLIGHTING CLINICAL AND ECONOMIC RATIONALE FOR VIVI CAP

Tempramed Technologies Ltd. has seen the publication of a clinical case report evaluating the use of Vivi Cap for passive thermal protection of insulin during summer travel.

The paper, titled "Passive Thermal Protection of In-Use Insulin During Summer Travel: Device Description and Single-Patient Case Report with a Simple Cost Perspective," was written by Tempramed's medical director, Prof. Andreas Pfutzner, and colleagues and published in the Journal of Clinical & Medical Case Reports (February, 2026).

The publication describes the use of Vivi Cap by a patient with Type 1 diabetes during sustained high ambient temperatures (35 to 38 C) while travelling in Greece. Compared with a prior month without thermal protection, the patient demonstrated:

• Improved time in range (86 per cent versus 82 per cent);
• Reduced time above 250 milligrams per decilitre (3 per cent versus 5 per cent);
• Stable mealtime insulin requirements despite extreme heat;
• No emergency department or urgent care visits.

Importantly, the report emphasizes not only glycemic stability but also reduced anxiety and increased patient confidence regarding insulin effectiveness in hot climates, factors that directly influence health care utilization and medication wastage.

Scientific evidence supporting economic validation

The publication explicitly references Tempramed's independently validated payer return-on-investment model, noting that the primary economic value of thermal protection lies not in minor dose differences, but in:

• Prevention of medication wastage due to suspected temperature excursions;
• Avoidance of heat-related glycemic deterioration;
• Reduction in emergency events such as severe hyperglycemia and diabetic ketoacidosis;
• Lower anxiety-driven health care utilization.

These are the same core drivers underlying Tempramed's payer savings model, which recently received third party validation for savings and metrics by the Validation Institute through January, 2027.

While the published case represents a single-patient observation, the authors conclude that the clinical findings are consistent with the mechanistic rationale of Vivi Cap's vacuum insulation and phase-change thermal buffering technology and support further prospective studies incorporating payer-relevant end points such as resource utilization and medication discard rates.

Strategic significance

Management views the publication as an important bridge between:

1. Clinical plausibility: peer-reviewed evidence demonstrating preserved insulin stability and improved patient confidence in extreme conditions; and
2. Health-economic validation: independent confirmation that the payer ROI model is methodologically credible and aligned with real-world savings pathways.

"This publication provides scientific context to the economic case we have already validated," said Ron Nagar, chief executive officer of Tempramed. "It highlights how thermal protection can translate into clinical stability and patient confidence in high-risk environments -- exactly the drivers incorporated into our validated payer ROI model. Together, clinical rationale and economic validation significantly strengthen our reimbursement discussions."

Reimbursement and market impact

As Tempramed continues assessing pilot programs and coverage decisions with various payers, the combination of the following points below further supports the company's strategy to position Vivi Cap as a reimbursable, cost-saving standard in diabetes management and other temperature-sensitive therapies:

• Published scientific rationale;
• Real-world use case illustration; and
• Independently validated economic modelling.

Management believes that continued publication, data generation and payer engagement represent key catalysts in expanding coverage, accelerating adoption and driving scalable revenue growth.

About Tempramed Technologies Ltd.

Tempramed is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered, space-grade thermal insulation devices that work 24-seven without batteries or external power. With a proven product line including Vivi Cap and Vivi Epi, and a smart technology platform on the horizon, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. Headquartered in Israel with operations in North America, Europe and Asia, Tempramed is advancing the future of medication protection and adherence.

We seek Safe Harbor.